Skip to main content

Table 1 Demographic and clinical characteristics of resected pancreatic cancer patients1

From: Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study

Variable

Category

The US

Belgium

The Netherlands

Slovenia

Norway

Incidence (per 100,000)2

Male

8.6

7.4

7.4

9.3

7.8

Female

6.5

5.6

6.1

6.5

6.5

Years of diagnosis

 

2004–2015

2004–2013

2003–2014

2003–2013

2003–2014

n

 

9519

1105

982

118

113

Diagnosis in 2010 or later

Yes

5635 (59)

579 (52)

747 (76)

67 (57)

79 (70)

Sex

Female

4671 (49)

522 (47)

483 (49)

50 (42)

58 (51)

Age (years)

Median (interquartile range)

65 (58–72)

65 (58–71)

64 (57–69)

61 (54–68)

63 (59–70)

Mean ± standard deviation

65 ± 10

64 ± 10

62 ± 9

61 ± 9

64 ± 8

< 50

706 (7)

90 (8)

92 (9)

11 (9)

4 (4)

50–59

2101 (22)

264 (24)

235 (24)

38 (32)

29 (26)

60–69

3464 (36)

406 (37)

417 (42)

46 (39)

50 (44)

≥ 70

3248 (34)

345 (31)

238 (24)

23 (19)

30 (27)

Tumor location3

Pancreas head

7314 (83)

658 (82)

820 (90)

97 (92)

91 (88)

Pancreas body

622 (7)

58 (7)

31 (3)

5 (5)

4 (4)

Pancreas tail

845 (10)

86 (11)

63 (7)

3 (3)

8 (8)

Other

738 (8)

303 (27)

68 (7)

13 (11)

10 (9)

T stage4

T1

494 (5)

56 (5)

72 (7)

0 (0)

8 (8)

T2

1192 (13)

185 (17)

182 (19)

8 (7)

28 (26)

T3

7815 (82)

860 (78)

727 (74)

108 (93)

70 (66)

N stage5

N1

6339 (67)

805 (73)

703 (72)

97 (84)

60 (55)

Differentiation6

Well

858 (10)

149 (15)

91 (11)

12 (11)

3 (3)

Intermediate

4540 (52)

511 (52)

423 (51)

44 (40)

64 (63)

Poor/undifferentiated

3266 (38)

326 (33)

319 (38)

55 (50)

35 (34)

  1. 1Categorical data are shown as count (percentage [%]). For brevity, results for the counterparts in dichotomous variables are omitted. Records are complete otherwise specified below
  2. 2The cancer incidence rates by sex in each country were retrieved from the Cancer Incidence in Five Continents Volume XI (CI5 XI) by the International Agency for Research on Cancer (IARC), World Health Organization (WHO) which reports the incidence of cancers diagnosed from 2008 to 2012, standardized to the World (WHO 2000–2025) Standard Population
  3. 3The percentages of pancreas head, body, tail, and overlapping cancers are the proportions compared to the total tumor cases of the four locations; “other” includes overlapping lesion, pancreas duct, and not otherwise specified location, and its proportion is relative to the whole cases
  4. 4Missing T stage: the US: 18 (< 1%); Belgium: 4 (< 1%); the Netherlands: 1 (< 1%); Slovenia: 2 (2%); Norway: 7 (6%)
  5. 5Missing N stage: the US: 0 (0%); Belgium: 7 (1%); the Netherlands: 0 (0%); Slovenia: 2 (2%); Norway: 3 (3%)
  6. 6Missing differentiation: the US: 855 (9%); Belgium: 119 (11%); the Netherlands: 149 (15%); Slovenia: 7 (6%); Norway: 11 (10%)